mercaptopurine monohydrate - Sökresultat

alphapharm pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; macrogol 8000; purified talc; sodium lauryl sulfate - indications as at 11 may 2001: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in idiopathic gout, uric acid lithiasis, acute uric acid nephropathy, neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. progout is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyltransferase. progout is indicated for the management of recurrent mixed calcium oxalate renal stones in the p

Australien - engelska - Department of Health (Therapeutic Goods Administration)

puri-nethol

aspen pharmacare australia pty ltd - mercaptopurine -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

lanvis tioguanine 40mg tablet bottle

aspen pharmacare australia pty ltd - tioguanine, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; stearic acid; magnesium stearate; potato starch; acacia - indications as at 10 october 2005: acute myeloblastic leukaemia. less commonly, chronic granulocytic (myelocytic, myeloid, myelogenous) leukaemia. although superior results are generally obtained with busulphan (myleran) in the treatment of chronic granulocytic leukaemia. lanvis may be useful during blast crises or periods of thrombocytopenia induced by busulphan or other therapy. a degree of cross resistance exists between lanvis (thioguanine) and puri-nethol (mercaptopurine) and generally it is not to be expected that patients who no longer respond to mercaptopurine will respond to thioguanine or vice versa. unlike mercaptopurine the detoxification of lanvis is not dependent on xanthine oxidase, hence therapy with lanvis is not affected by the xanthine oxidase inhibitor, allopurinol (zyloprim). recent evidence suggests that lanvis is particularly useful in concurrent or sequelist combination with other antineoplastic drugs, e.g., cytosine arabinoside. not effective for the treatment of chronic lymphocytic l